Real-World Data Shows Tirzepatide's Lasting Benefits for Obesity-Related Health

Obesity is a global health crisis, often leading to the development of Cardio-Metabolic-Kidney Syndrome (CMKD), a complex cluster of interconnected conditions including type 2 diabetes, cardiovascular disease, and chronic kidney disease. While Tirzepatide, a dual GIP/GLP-1 receptor agonist, has demonstrated significant efficacy in clinical trials for weight loss and glycemic control, there is a critical need for real-world evidence to understand its long-term effectiveness on these multifaceted CMKD outcomes, especially how treatment persistence impacts these benefits outside of controlled trial settings.

Patients demonstrating high persistence with Tirzepatide showed significantly superior improvements across all measured cardio-metabolic-kidney outcomes compared to those with low persistence. The highly persistent group achieved an average weight loss of 18.5% (p<0.001) from baseline, which was more than double the 7.2% average weight loss observed in the low-persistence group. > HbA1c levels, a key marker for glycemic control, decreased by an impressive 2.1% (p<0.001) in persistent users, representing a 2.5-fold greater reduction than the 0.8% seen in non-persistent users. Furthermore, persistent Tirzepatide use led to significant reductions in blood pressure, with average decreases of 12 mmHg in systolic blood pressure (p<0.005) and 7 mmHg in diastolic blood pressure (p<0.01). Crucially, markers of kidney function, such as eGFR, stabilized or improved in 75% of highly persistent patients, contrasting sharply with only 30% in the less persistent cohort.